David P Serota1, Eli S Rosenberg2, Patrick S Sullivan3, Annie L Thorne4, Charlotte-Paige M Rolle5, Carlos Del Rio1,6, Scott Cutro7, Nicole Luisi3, Aaron J Siegler4, Travis H Sanchez3, Colleen F Kelley1. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Department of Epidemiology and Biostatistics, University of Albany School of Public Health, State University of New York, Rensselaer, New York, USA. 3. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA. 4. Department of Behavioral Science and Health Education, Emory University Rollins School of Public Health, Atlanta, Georgia, USA. 5. Orlando Immunology Center, Orlando, Florida, USA. 6. Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia, USA. 7. Department of Infectious Diseases, Kaiser Permanente, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has great potential to reduce HIV incidence among young black men who have sex with men (YBMSM); however, initiation and persistence for this group remain low. We sought to understand the patterns and predictors of PrEP uptake and discontinuation among YBMSM in Atlanta, Georgia. METHODS: PrEP was offered to all participants in a prospective cohort of YBMSM aged 18-29 years not living with HIV. Time to PrEP uptake, first discontinuation, and final discontinuation were assessed using the Kaplan-Meier method. Cox proportional hazard models were used to identify predictors of uptake and discontinuation. RESULTS: After 440 person-years of follow-up, 44% of YBMSM initiated PrEP through the study after a median of 122 days. Of PrEP initiators, 69% had a first discontinuation and 40% had a final discontinuation during the study period. The median time to first PrEP discontinuation was 159 days. Factors associated with PrEP uptake included higher self-efficacy, sexually transmitted infection (STI), and condomless anal intercourse. Factors associated with discontinuation included younger age, cannabis use, STI, and fewer sex partners. HIV incidence was 5.23/100 person-years (95% confidence interval [CI], 3.40-7.23), with a lower rate among those who started PrEP (incidence rate ratio, 0.39; 95% CI, .16-.92). CONCLUSIONS: Persistent PrEP coverage in this cohort of YBMSM was suboptimal, and discontinuations were common despite additional support services available through the study. Interventions to support PrEP uptake and persistence, especially for younger and substance-using YBMSM, are necessary to achieve full PrEP effectiveness. CLINICAL TRIALS REGISTRATION: NCT02503618.
BACKGROUND: Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has great potential to reduce HIV incidence among young black men who have sex with men (YBMSM); however, initiation and persistence for this group remain low. We sought to understand the patterns and predictors of PrEP uptake and discontinuation among YBMSM in Atlanta, Georgia. METHODS: PrEP was offered to all participants in a prospective cohort of YBMSM aged 18-29 years not living with HIV. Time to PrEP uptake, first discontinuation, and final discontinuation were assessed using the Kaplan-Meier method. Cox proportional hazard models were used to identify predictors of uptake and discontinuation. RESULTS: After 440 person-years of follow-up, 44% of YBMSM initiated PrEP through the study after a median of 122 days. Of PrEP initiators, 69% had a first discontinuation and 40% had a final discontinuation during the study period. The median time to first PrEP discontinuation was 159 days. Factors associated with PrEP uptake included higher self-efficacy, sexually transmitted infection (STI), and condomless anal intercourse. Factors associated with discontinuation included younger age, cannabis use, STI, and fewer sex partners. HIV incidence was 5.23/100 person-years (95% confidence interval [CI], 3.40-7.23), with a lower rate among those who started PrEP (incidence rate ratio, 0.39; 95% CI, .16-.92). CONCLUSIONS: Persistent PrEP coverage in this cohort of YBMSM was suboptimal, and discontinuations were common despite additional support services available through the study. Interventions to support PrEP uptake and persistence, especially for younger and substance-using YBMSM, are necessary to achieve full PrEP effectiveness. CLINICAL TRIALS REGISTRATION: NCT02503618.
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Samuel M Jenness; Kevin M Maloney; Dawn K Smith; Karen W Hoover; Steven M Goodreau; Eli S Rosenberg; Kevin M Weiss; Albert Y Liu; Darcy W Rao; Patrick S Sullivan Journal: Am J Epidemiol Date: 2019-04-01 Impact factor: 4.897
Authors: Aaron J Siegler; Farah Mouhanna; Robertino Mera Giler; Kevin Weiss; Elizabeth Pembleton; Jodie Guest; Jeb Jones; Amanda Castel; Howa Yeung; Michael Kramer; Scott McCallister; Patrick S Sullivan Journal: Ann Epidemiol Date: 2018-06-15 Impact factor: 3.797
Authors: Sarah K Calabrese; Douglas S Krakower; Tiara C Willie; Trace S Kershaw; Kenneth H Mayer Journal: Clin Infect Dis Date: 2019-08-16 Impact factor: 9.079
Authors: Susanne Doblecki-Lewis; Albert Y Liu; Daniel J Feaster; Stephanie E Cohen; Richard Elion; Oliver Bacon; Megan Coleman; Gabriel Cardenas; Michael A Kolber Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Laura Whiteley; Lacey Craker; Shufang Sun; Nicholas Tarantino; Dylan Hershkowitz; Jesse Moskowitz; Trisha Arnold; Kayla Haubrick; Elizabeth Olsen; Leandro Mena; Larry K Brown Journal: J HIV AIDS Soc Serv Date: 2021-08-06
Authors: Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico Journal: Curr HIV/AIDS Rep Date: 2022-06-14 Impact factor: 5.495
Authors: Krishna Kiran Kota; Gordon Mansergh; Rob Stephenson; Sabina Hirshfield; Patrick Sullivan Journal: AIDS Patient Care STDS Date: 2021-04-23 Impact factor: 5.078
Authors: Whitney C Sewell; Victoria E Powell; Kenneth H Mayer; Aileen Ochoa; Douglas S Krakower; Julia L Marcus Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771
Authors: Meagan Zarwell; Steven A John; Drew Westmoreland; Chloe Mirzayi; David W Pantalone; Sarit Golub; Denis Nash; Christian Grov Journal: AIDS Behav Date: 2020-10-15
Authors: Wenting Huang; Annie Lockard; Colleen F Kelley; David P Serota; Charlotte-Paige M Rolle; Patrick S Sullivan; Eli S Rosenberg; Aaron J Siegler Journal: AIDS Care Date: 2021-08-09